Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L. Simpson, Marius Ardeleanu, Thomas Bieber et al.|New England Journal of Medicine|2016Cited by 2k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al.|British Journal of Dermatology|2020Cited by 590
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S. Paller, Brad Shumel, John D. Davis et al.|Journal of the American Academy of Dermatology|2020Cited by 385
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trialsEric L. Simpson, Kristian Reich, J.‐P. Lacour et al.|British Journal of Dermatology|2020Cited by 377
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritusJonathan I. Silverberg, Alan Clucas, Andreas Pinter et al.|Journal of Allergy and Clinical Immunology|2019Cited by 268